Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis

American Journal of Gastroenterology

Volumn 114, Issue 7, 2019, Pages 1043-1050

  Xu, Dabo ^a   Chen, Vincent L ^a   Steiner, Calen A ^a   Berinstein, Jeffrey A ^a   Eswaran, Shanti ^a   Waljee, Akbar K ^a   Higgins, Peter D R ^a   Owyang, Chung ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

COLONOSCOPY; DIARRHEA; FECAL MICROBIOTA TRANSPLANTATION; FECES MICROFLORA; HUMAN; IRRITABLE COLON; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VERTIGO; FEMALE; INTESTINE FLORA; MALE; PROCEDURES; PROGNOSIS; PSYCHOLOGY; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

FECAL MICROBIOTA TRANSPLANTATION; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85066397004     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.14309/ajg.0000000000000198     Document Type: Review

References (42)

1. Owyang C,. Irritable bowel syndrome. In: Kasper D, Fauci A, Hauser S, et al (eds). Harrison's Principles of Internal Medicine, 19th edn. McGraw-Hill Education: New York, NY, 2015, pp 1965-70.
2. Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology 2016; 150: 1393-407.e5.
3. Sperber AD, Dumitrascu D, Fukudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome foundation working team literature review. Gut 2017; 66: 1075-82.
4. Ford AC, Bercik P, Morgan DG, et al. Characteristics of functional bowel disorder patients: A cross-sectional survey using the Rome III criteria. Aliment Pharmacol Ther 2014; 39: 312-21.
5. Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000; 119: 654-60.
6. Peery AF, Crockett SD, Barritt AS, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology 2015; 149: 1731-41.e3.
7. Chey WD, Kurlander J, Eswaran S,. Irritable bowel syndrome: A clinical review. JAMA 2015; 313: 949-58.
8. El-Serag HB, Pilgrim P, Schoenfeld P,. Systemic review: Natural history of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 861-70.
9. Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminal-and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011; 301: G799-807.
10. Carroll IM, Ringel-Kulka T, Siddle JP, et al. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 521-30, e248.
11. Bhattarai Y, Muniz Pedrogo DA, Kashyap PC,. Irritable bowel syndrome: A gut microbiota-related disorder? Am J Physiol Gastrointest Liver Physiol 2017; 312: G52-62.
12. Tap J, Derrien M, Tornblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 2017; 152: 111-23.e8.
13. Menees S, Chey W,. The gut microbiome and irritable bowel syndrome. F1000Res 2018; 7: F1000.
14. Foxx-Orenstein AE, Chey WD,. Manipulation of the gut microbiota as a novel treatment strategy for gastrointestinal disorders. Am J Gastroenterol Suppl 2012; 1: 41-6.
15. Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: A systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 28-36; quiz 36.
16. Chey J, Ford AC, Yuan Y, et al. A systematic review and meta-analysis evaluating the efficacy of a gluten-free diet and a low FODMAPs diet in treating symptoms of irritable bowel syndrome. Am J Gastroenterol 2018; 113: 1290-300.
17. Kassam Z, Lee CH, Yuan Y, et al. Fecal microbiota transplantation for Clostridium difficile infection: Systematic review and meta-analysis. Am J Gastroenterol 2013; 108: 500-8.
18. Hunt S, Brummer RJ, Repsilber D, et al. Fecal microbiota transplantation in irritable bowel syndrome and a randomized placebo-controlled trial. Gastroenterology 2017; 152: S101-2.
19. Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: A double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol 2018; 3: 17-24.
20. Holvoet T, Joossens M, Jerina B, et al. Fecal microbiota transplantation in irritable bowel syndrome with predominant abdominal bloating: Results from a double blind, placebo-controlled clinical trial. Gastroenterology 2018; 154: S130.
21. Halkjaer SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: Results from a randomised, double-blind placebo-controlled study. Gut 2018; 67: 2107-15.
22. Aroniadis OC, Brandt LJ, Oneto C, et al. A double-blind, randomized, placebo-controlled trial of fecal microbiota transplantation capsules (FMTC) for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Gastroenterology 2018; 154: S154-55.
23. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of observational studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
24. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med 2009; 151: 264-9, W64.
25. Irvine EJ, Tack J, Crowell MD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2016; 150: 1469-80.e1.
26. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, et al. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45 (Suppl 2): II69-77.
27. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
28. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383-94.
29. GRADEpro GDT: GRADEpro guideline development tool [software]. McMaster University, 2015 (developed by Evidence Prime, Inc., gradepro.org).
30. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343: d4002.
31. Bruno G, Cicerone C, Auria S, et al. Fecal microbiota transplantation in patients with irritable bowel syndrome unresponsive to standard treatments: Transplant protocol via retention enema and preliminary results. Dig Liver Dis 2018; 50: e175.
32. El-Salhy M, Holger Johnsen P, Mazzawi T, et al. Effect of faecal microbiota transplantation on the enteroendocrine cells of the colon in patients with irritable bowel syndrome (IBS): Double blinded-placebo controlled study. Neurogastroenterol Motil 2017; 29: 71.
33. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014; 312: 1772-8.
34. Wang S, Xu M, Wang W, et al. Systematic review: Adverse events of fecal microbiota transplantation. PLoS One 2016; 11: e0161174.
35. Kao D, Roach B, Silva M, et al. Effect of oral capsule-vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: A randomized clinical trial. JAMA 2017; 318: 1985-93.
36. Shah E, Pimentel M,. Placebo effect in clinical trial design for irritable bowel syndrome. J Neurogastroenterol Motil 2014; 20: 163-70.
37. Marteau P, Pochart P, Doré J, et al. Comparative study of bacterial groups within the human cecal and fecal microbiota. Appl Environ Microbiol 2001; 67: 4939-42.
38. Zmora N, Zilberman-Schapira G, Suez J, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell 2018; 174: 1388-405.e21.
39. Tropini C, Moss EL, Merrill BD, et al. Transient osmotic perturbation causes long-term alteration to the gut microbiota. Cell 2018; 173: 1742-1754.e17.
40. Cleusix V, Lacroix C, Vollenweider S, et al. Glycerol induces reuterin production and decreases Escherichia coli population in an in vitro model of colonic fermentation with immobilized human feces. FEMS Microbiol Ecol 2008; 63: 56-64.
41. Ford AC, Moayyedi P,. Meta-analysis: Factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther 2010; 32: 144-58.
42. Halkjaer SI, Boolsen AW, Gunther S, et al. Can fecal microbiota transplantation cure irritable bowel syndrome? World J Gastroenterol 2017; 23: 4112-20.